About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform


Rexahn Announces the Appointment of Peter Brandt as Chairman of the Board


More


Portfolio